Manuela Colafigli

Summary

Country: Italy

Publications

  1. ncbi Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of S Heart, Rome, Italy
    Clin Microbiol Infect 18:E299-304. 2012
  2. ncbi Long-term follow-up of nevirapine-treated patients in a single-centre cohort
    Manuela Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    HIV Med 10:461-9. 2009
  3. ncbi Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 9:172-9. 2008
  4. ncbi Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
  5. ncbi Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
  6. ncbi Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
  7. ncbi Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
  8. ncbi Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
  9. ncbi Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
    Mattia C F Prosperi
    Viral Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    BMC Infect Dis 12:296. 2012
  10. ncbi The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 27:1299-309. 2011

Detail Information

Publications12

  1. ncbi Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of S Heart, Rome, Italy
    Clin Microbiol Infect 18:E299-304. 2012
    ..TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR...
  2. ncbi Long-term follow-up of nevirapine-treated patients in a single-centre cohort
    Manuela Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    HIV Med 10:461-9. 2009
    ..We reviewed the safety and efficacy of nevirapine (NVP)-based therapy in all patients initiating NVP-containing combined antiretroviral therapy [cART (>or=3 drugs)] in our clinic since 1994...
  3. ncbi Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 9:172-9. 2008
    ....
  4. ncbi Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
    ..The achievement of virological suppression is a strong predictor of reduced clinical progression...
  5. ncbi Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
    ..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort...
  6. ncbi Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    ..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed...
  7. ncbi Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
    ..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir...
  8. ncbi Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
    ..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)...
  9. ncbi Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
    Mattia C F Prosperi
    Viral Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    BMC Infect Dis 12:296. 2012
    ..However, its determinants are not fully understood. Aim of this study was to investigate predictors of first-line antiretroviral therapy discontinuation due to adverse events and their evolution in recent years...
  10. ncbi The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 27:1299-309. 2011
    ..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions...
  11. ncbi Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia
    Nicoletta Ciccarelli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 18:153-60. 2013
    ..The objective of our study was to compare two different central nervous system penetration-effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients...
  12. ncbi Interpretation systems for genotypic drug resistance of HIV-1
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, , Rome, Italy
    Scand J Infect Dis Suppl 35:29-34. 2003
    ..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation...